icometrix

icometrix operates in the clinical neuroimaging software segment, where its differentiation is the conversion of routine MRI and CT scans into standardized, quantitative biomarkers rather than relying only on image viewing or general radiology workflow tools. Its product portfolio spans multiple sclerosis, Alzheimer’s disease, dementia, epilepsy, tumors, stroke, and traumatic brain injury, giving it broader neurological coverage than a single-disease imaging specialist. icobrain aria adds a focused safety-monitoring use case for amyloid-targeting Alzheimer’s therapies, while icobrain supports automated lesion and volumetric analysis. The company’s stated compatibility with MRI systems from major manufacturers and integration layer for scanners, PACS, and electronic medical records address deployment barriers that can limit hospital adoption. Relevant competitive pressure comes from large imaging-platform vendors such as GE Healthcare, Siemens Healthineers, and Philips, as well as specialist AI companies including Brainomix and QMENTA. GE Healthcare’s acquisition of icometrix on Sep 10, 2025 changes the competitive context: icometrix now combines specialist neuroimaging algorithms and regulatory experience with the reach of a global equipment and healthcare-technology provider.

icometrix’s trajectory shows a progression from university spin-off to regulated clinical software provider and, ultimately, strategic acquisition. Founded in 2011 by Dirk Loeckx and Wim Hecke, the company raised a $2,000,000-equivalent venture round on Jan 13, 2016, followed by an $18,000,000 Series A led by Forestay Capital on May 14, 2019. Two grants in March 2023 added approximately $1.71 million in disclosed converted value and extended support from NHS England and the Michael J. Fox Foundation. The company’s product expansion has been a key inflection point: its original MS-focused imaging capabilities broadened into icobrain products for dementia, epilepsy, tumors, and Alzheimer’s-treatment monitoring. The Nov 14, 2024 launch of icobrain aria marked a move into a rapidly developing therapeutic-monitoring workflow, while cloud-enabled deployment described in 2023 supports scale across hospitals and research programs. The company reported a team of more than 25 people in its operating description and is categorized in the 51–100 employee range, although the exact current headcount is unavailable. GE Healthcare’s 2025 acquisition is the latest major trajectory inflection point, shifting icometrix from venture-backed expansion toward integration with a global healthcare-technology owner.